Egg Effects on Atherogenic Dyslipidemias, Glucose Metabolism and Inflammation in Diabetic Subjects

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT02181244
• Date of registration: 20/06/2014
• Prospective Registration: No
• Primary sponsor: University of Connecticut
• Public title: Egg Effects on Atherogenic Dyslipidemias, Glucose Metabolism and Inflammation in Diabetic Subjects
• Scientific title: Egg Effects on Atherogenic Dyslipidemia, Glucose Metabolism and Inflammation in Diabetic Subjects
• Date of first enrolment: May 2013
• Target sample size: 33
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT02181244
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
• Phase: N/A

Countries of recruitment

Mexico

Contacts

• Name: Maria-Luz Fernandez, PhD
• Affiliation: University of Connecticut

Key inclusion & exclusion criteria

Inclusion Criteria:

- diabetic subjects diagnosed by physician

- male and female

- 35-65 years

- Glycosylated hemoglobin < 9%

Exclusion Criteria:

- taking ezetimibe

- heart disease

- renal problems

- cancer

- thyroid problems



Age minimum: 35 Years
Age maximum: 65 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Inflammation

Diabetes Mellitus

Intervention(s)

Other: Egg, one a day, for breakfast

Other: Oatmeal, one cup a day

Primary Outcome(s)

glycosylated hemoglobin [Time Frame: Assessed at base line and at the end of 5 weeks after the consumption of eggs and at the end of 5 weeks after the consumption of oatmeal]

Secondary Outcome(s)

plasma LDL cholesterol [Time Frame: Measured at baseline and 5 weeks after the consuming the eggs and 5 weeks after consuming the oatmeal]

Secondary ID(s)

H12-059

Source(s) of Monetary Support

Please refer to primary and secondary sponsors